← All companies

LENZ

LENZ Therapeutics, Inc.

LENZ Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$5.00

-0.30 -5.75%

Key statistics

from XBRL data in SEC filings

Market cap

$157M

Revenue (TTM)

$21.0M

Net income (TTM)

-$109M

EPS (TTM)

$-3.64

P/E ratio

—

Dividend yield

—

Free cash flow

-$70.0M

Cash

$24.8M

Total assets

$273M

Gross margin

—

52-week range

$4.68 – $50.40

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Director or officer change Jul 2, 2026 8-K Shareholder vote results Jun 12, 2026 10-Q Quarter ended 2026-03-31 May 11, 2026 8-K Results of operations (earnings release) May 11, 2026 10-K Fiscal year ended 2025-12-31 Mar 24, 2026 8-K Results of operations (earnings release) Mar 24, 2026 8-K Results of operations (earnings release) Jan 7, 2026 8-K Other events Dec 12, 2025 10-Q Quarter ended 2025-09-30 Nov 5, 2025 8-K Results of operations (earnings release) Nov 5, 2025 8-K Other events Oct 8, 2025 8-K Regulation FD disclosure; Other events Sep 30, 2025 8-K Other events Jul 31, 2025 10-Q Quarter ended 2025-06-30 Jul 30, 2025 8-K Results of operations (earnings release) Jul 30, 2025 8-K Shareholder vote results Jun 10, 2025 10-Q Quarter ended 2025-03-31 May 7, 2025 8-K Results of operations (earnings release) May 7, 2025 8-K Results of operations (earnings release); Regulation FD disclosure; Other events Apr 15, 2025 8-K Entered a material agreement Apr 4, 2025 10-K Fiscal year ended 2024-12-31 Mar 19, 2025 8-K Results of operations (earnings release) Mar 19, 2025 10-Q Quarter ended 2024-09-30 Nov 6, 2024 8-K Results of operations (earnings release) Nov 6, 2024 8-K Other events Oct 28, 2024 10-Q Quarter ended 2024-06-30 Aug 14, 2024 8-K Results of operations (earnings release) Aug 14, 2024 8-K Other events Aug 12, 2024 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure Jul 15, 2024 10-Q Quarter ended 2024-03-31 May 8, 2024 8-K Results of operations (earnings release) May 8, 2024 8-K Other events Apr 3, 2024 8-K Completed an acquisition or disposition; Unregistered sale of equity; Modified rights of security holders; Changed accountants; Change in control; Director or officer change; Amended charter or bylaws; Item 5.05; Item 5.06; Regulation FD disclosure Mar 22, 2024 8-K Regulation FD disclosure Mar 19, 2024 8-K Shareholder vote results Mar 14, 2024 8-K Regulation FD disclosure Mar 8, 2024 8-K Other events Mar 5, 2024 10-K Fiscal year ended 2023-12-31 Feb 27, 2024 8-K Other events Dec 26, 2023 8-K Entered a material agreement; Unregistered sale of equity; Change in control; Director or officer change; Regulation FD disclosure Nov 15, 2023